Konekt takes advantage of dominant position in workplace injury industry
There are few situations more demoralising than being unable to work due to health problems. Health issues can be a pre-existing or unrelated conditions not linked with the person’s place of employment, or on the other hand, the workplace can be the very reason why an employee is suffering an injury or illness.
Regardless of the circumstances, not only are these issues prominent in the minds of individuals, they are also at the forefront of strategies and funding undertaken at both the government and corporate level.
Australia’s largest provider of organisational health, risk management and return to work solutions, Konekt (ASX: KKT) provided some interesting data when it delivered an impressive fiscal 2017 result earlier this month.
The company noted that Federal Government funding for the jobactive program is approximately $1.4 billion per annum through to fiscal 2020. Konekt has valuable relationships at a government level in terms of maximising workforce participation through its expertise in the areas of injury management and return to work programs.
The following graph which reflects data from the Department of Employment Budget Statements demonstrates the uptick in spending in this area since 2016, and the proposed substantial investment through to fiscal 2021.
Industry leading position in niche fragmented market with high barriers to entry.
As part of its role as Australia’s leading provider of return to work solutions, KKT also provides employers with strategies regarding injury prevention and/or the minimisation of workplace injury, effectively minimising the costs and drags on productivity which are normally associated with employee injuries.
KKT has over 350 allied health professionals providing workplace and injury management services to its clients and their employees. It is the industry leader in this segment with a market share of circa 12%.
KKT’s clients include major employers in both public and private sectors, as well as Australia’s largest insurance companies.
While KKT is the industry leader, the market remains highly fragmented and opportunities for growth by acquisition have assisted the company and growing revenues and entering new markets/regions. Working in KKT’s favour is the fact that it has a strong balance sheet and on this note the company was debt free as at June 30, 2017.
However, investors should still seek professional financial advice for further information if considering this stock for their portfolio.
However, an opportunity to acquire a business which was both complementary and provided access to revenues from a relatively new industry segment emerged in August. KKT was able to complete the $24 million acquisition of Mission Providence with the assistance of a part placement and rights issue.
Transformational acquisition to provide the next leg of growth
Mission Providence is a leading provider of employment services and the New Enterprise Incentive Scheme (NEIS) under the Federal Government’s jobactive program. The enterprise is a joint venture between Mission Australia and the Providence Service Corporation (US).
Mission Providence is one of 43 providers holding a jobactive contract with the Federal Government’s Department of Employment. The contract has nearly 3 more years to run when it is expected to be put up for review prior to expiry, which may include tender, rollover or restructuring of the program. NEIS revenues represented 15% of the group’s fiscal 2017 income.
Commenting on the acquisition, KKT Managing Director, Damien Banks said, “The acquisition of Mission Providence makes strategic sense for our business and delivers value for all our stakeholders, enabling us to expand into adjacent employment markets with scale, consistent with our focus and purpose of maximising outcomes for the individuals with whom we work.”
Fundamentals look attractive
On a pro-forma basis the merged business is expected to approximately double revenue and EBITDA while delivering earnings per share (before amortisation) accretion of 20% in fiscal 2018.
While the earnings per share impact will be even more pronounced in fiscal 2019, crunching the numbers relative to the company’s fiscal 2017 result indicates that KKT is in a fundamentally strong position, and perhaps undervalued relative to its current share price.
The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance
The company’s fiscal 2017 underlying net profit of $3.2 million represented earnings per share of 4.4 cents, implying year-on-year growth of 15%. An increase of 20% in fiscal 2018 would translate into earnings per share of approximately 5.3 cents.
This indicates that the company is trading on a PE multiple of approximately 10. Given its demonstrated ability to generate strong growth in recent years, while also taking into account the robust incremental impact of the Mission Providence acquisition, it wouldn’t be surprising to see the company trade on a more aggressive multiple once the financial impact of the acquisition begins to materialise.
However, it is worth noting that management has an established record of delivering strong growth while maintaining financial discipline, and this is reflected in the following four year data shot which also encompasses guidance incorporating the acquisition.
Management has demonstrated its ability to efficiently integrate acquisitions
This raises the question as to whether investors are perhaps better off snapping up KKT at what would appear a discount price, or whether it would pay to wait for evidence to emerge regarding the fiscal 2018 earnings outlook based on the success of the acquisition, as well as the traditional organic earnings growth that the company has been able to generate over the last four years.
Regards the latter it would pay to bear in mind that KKT should benefit from a number of developments that occurred in the last 12 months including the execution of a new Medibank health solutions contract in May 2017, its panel appointment in the Commonwealth Government sector and its appointment to icare New South Wales Workers Compensation panel for fiscal 2018.
On the score of assessing its ability to efficiently integrate Mission Providence, it is worth considering the fact that management has in the past successfully bedded down businesses acquired in various sectors of its operations, including SRC Solutions and CommuniCorp in 2016, with the latter improving its position in the high-growth psychological health market segment.
The company has a healthy spread of income across geographic regions, and the fact that it generates revenues from multiple sources such as the government sector, corporations and insurance companies helps to provide insulation against one-off events such as contract losses.
As indicated in the graphs below, the company also generates revenue from injury management which many corporations see as an investment rather than an expense. This is often the source of recurring income as KKT provides ongoing services to its existing client base.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.